TriLink BioTech, part of Maravai LifeSciences, is a leading contract development and manufacturing organization (CDMO) specializing in nucleic acid synthesis. They offer a wide range of cutting-edge products and services for gene therapy, nucleoside chemotherapy, oligonucleotide therapy, and next-generation sequencing (NGS). TriLink's expertise lies in the synthesis of nucleic acids, NTPs, and mRNA capping analogs.

They have unique capabilities in mRNA, oligonucleotide, and plasmid production, making them a trusted partner for companies focused on therapeutic, vaccine, diagnostic, and biopharmaceutical breakthroughs. One of TriLink's key innovations is their proprietary CleanCap® mRNA co-transcriptional capping technology, which simplifies mRNA manufacturing and improves efficiency and yields. They also provide custom nucleic acid chemistry, oligo manufacturing, and analytical services.

With their state-of-the-art cGMP manufacturing facility and commitment to quality and compliance, TriLink supports customers from initial research phases to clinical trials. Their dedication to innovation and over 25 years of industry leadership in nucleic acid synthesis sets them apart in the field. Discover more about TriLink BioTech and their groundbreaking products and services on their website